Finance

Lists
WST:NYSE
West Pharmaceutical Services Inc
374,00 $
-0,70%
(-2,62) 1D
30 қыр., 12:26:11 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WST...
Open
375,35 $
High
376,19 $
Low
371,38 $
Mkt. cap
26,31 млрд
Avg. vol.
562,61 м.
Volume
84,79 мың
Dividend
0,24%
Quarterly dividend
0,22 $
Ex-dividend date
2026 ж. 29 шіл.
P/E ratio
47,81
52-wk high
386,00 $
52-wk low
223,83 $
EPS
7,82 $
Beta
1,14
Shares outstanding
70,38 млн
No. of employees
11 мың
Open
375,35 $
High
376,19 $
Low
371,38 $
Mkt. cap
26,31 млрд
Avg. vol.
562,61 м.
Volume
84,79 мың
Dividend
0,24%
Quarterly dividend
0,22 $
Ex-dividend date
2026 ж. 29 шіл.
P/E ratio
47,81
52-wk high
386,00 $
52-wk low
223,83 $
EPS
7,82 $
Beta
1,14
Shares outstanding
70,38 млн
No. of employees
11 мың
News stories
From web sources and news partners
Profile
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin. Wikipedia
About West Pharmaceutical Services Inc
CEOEric M. Green
Employees10,8 мың
Founded1923
HeadquartersWest Whiteland Township, Пенсильвания, Америка Құрама Штаттары
Sector-
Analyst ratings
Based on 10 analysts giving stock ratings to WST in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for WST in the last 3 months.
Highest
Current 374,00 $
447,00 $ (+19,52%)
Average
412,11 $ (+10,19%)
Lowest
390,00 $ (+4,28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kallum Titchmarsh
Morgan Stanley
Buy
Upgraded
400,00 $
+7%
09/22/2026
Unknown Analyst
UBS
Buy
Maintained
415,00 $
+11%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
415,00 $
+11%
09/09/2026
Joanne Wuensch
Citi
Buy
Maintained
412,00 $
+10,2%
08/03/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
425,00 $
+13,6%
07/27/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
410,00 $
+9,6%
07/24/2026
Luke Sergott
Barclays
Buy
Maintained
400,00 $
+7%
07/24/2026
Brendan Smith
TD Cowen
Buy
Reiterated
410,00 $
+9,6%
07/23/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/23/2026
Curtis Moiles
Exane BNP Paribas
Buy
Initiated
447,00 $
+19,5%
07/13/2026
Paul Knight
KeyBanc
Buy
Maintained
390,00 $
+4,3%
07/02/2026
Michael Polark
Wolfe Research
Buy
Reiterated
375,00 $
+0,3%
06/01/2026
Patrick B Donnelly
Citi
Buy
Maintained
400,00 $
+7%
04/24/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
-
-
04/23/2026
Dan Leonard
UBS
Buy
Maintained
340,00 $
-9,1%
02/13/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
315,00 $
-15,8%
02/13/2026
David Windley
Jefferies
Buy
Maintained
295,00 $
-21,1%
02/10/2026
Nico Chen
DBS
Buy
Maintained
320,00 $
-14,4%
01/28/2026
Last report
2026 ж. 23 шіл.
Fiscal period
Q2 2026
EPS / Est. (USD)
2,37 $ / 2,08 $
+13,86%beat
Revenue / Est. (USD)
872,30 млн / 839,98 млн
+3,85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
804,60 млн
805,00 млн
844,90 млн
872,30 млн
Cost of goods sold
510,30 млн
501,10 млн
548,50 млн
543,10 млн
Cost of revenue
510,30 млн
501,10 млн
548,50 млн
543,10 млн
Research and development expenses
17,10 млн
21,80 млн
15,80 млн
19,70 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
101,10 млн
107,50 млн
99,50 млн
112,00 млн
Operating expense
118,50 млн
129,70 млн
113,10 млн
133,20 млн
Total operating expenses
628,80 млн
630,80 млн
661,60 млн
676,30 млн
Operating income
175,80 млн
174,20 млн
183,30 млн
196,00 млн
Other non operating income
-200,00 м.
600,00 м.
-200,00 м.
-200,00 м.
EBT including unusual items
174,00 млн
165,40 млн
183,50 млн
186,20 млн
EBT excluding unusual items
179,50 млн
181,20 млн
188,60 млн
201,20 млн
Income tax expense
34,00 млн
33,30 млн
44,70 млн
32,20 млн
Effective tax rate
19,54%
20,13%
24,36%
17,29%
Other operating expenses
300,00 м.
400,00 м.
-2,20 млн
1,50 млн
Net income
140,00 млн
132,10 млн
138,80 млн
154,00 млн
Net profit margin
17,40%
16,41%
16,43%
17,65%
Earnings per share
1,96
2,04
2,13
2,37
Interest and investment income
4,70 млн
5,30 млн
5,10 млн
3,80 млн
Interest expense
-200,00 м.
-
-1,90 млн
-2,60 млн
Net interest expenses
4,50 млн
5,30 млн
3,20 млн
1,20 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
218,80 млн
221,20 млн
228,50 млн
242,20 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары